Biocon not to rush generic semaglutide to packed India market, says incoming CEO Shreehas Tambe
Published on: March 27, 2026, 10:34 p.m. | Source: The Economic Times
Biocon will delay its Indian launch of semaglutide. The company is focusing on international markets for the diabetes and weight-management drug. Biocon aims to become a global medicines company driven by innovation. Insulin remains a strategic anchor. Oncology and immunology are key pillars. New areas like ophthalmology are being explored. Investments will target technology and AI.
